文献速递其他结缔组织病

系统性硬化症疾病修饰定义的概念框架及其对药物研发和临床研究设计的潜在意义

Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design.
PubMed 文献 · Ann Rheum Dis · 2026-09-14

该文通过SSc专家共识方法,探讨在系统性硬化症(SSc)中定义疾病修饰所面临的挑战,并提出首个涵盖血管、炎症和纤维化三大领域的SSc疾病修饰定义框架。作者强调疾病修饰治疗应靶向核心通路或细胞而非调节机制,并应在疾病活动度及多器官损伤进展上显示持续效应,且需在临床前研发和临床试验设计中体现SSc的异质性。

要点

  • SSc疾病修饰定义需综合分子、机制和临床层面,并反映疾病异质性。
  • 疾病修饰治疗应靶向核心通路或细胞,而非调节机制。
  • 疾病修饰治疗需在疾病活动度和多器官损伤进展上显示持续效应。

核心结论

  • 提出首个涵盖血管、炎症和纤维化领域的SSc疾病修饰定义框架,强调需综合分子、机制和临床层面进行细致定义。

研究设计与样本

  • 采用SSc专家共识方法,旨在识别当前定义SSc疾病修饰的挑战。

主要发现

  • SSc分子改变和临床表现高度异质,患者间差异显著,阻碍了统一实用的疾病修饰定义。
  • 疾病修饰治疗应靶向核心通路或细胞而非调节机制,并应在疾病活动度和多器官损伤进展上显示持续效应。
  • SSc的复杂多变特性需反映在临床前药物研发和临床试验设计中,以证明候选药物的疾病修饰效应。

关键数值与推荐

  • 疾病修饰治疗应靶向核心通路或细胞而非调节机制。
  • 疾病修饰治疗应显示对疾病活动度的持续效应,并预防跨器官、表现、疾病阶段和疾病内型的损伤进展。

临床怎么用

  • 在SSc药物研发和临床试验设计中,需体现疾病异质性,并针对血管、炎症和纤维化领域评估疾病修饰效应。

局限性

  • 当前定义疾病修饰的挑战尚未完全解决,需随着对SSc细胞和分子机制理解的深入进一步细化定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic sclerosis (SSc) is a multifaceted systemic autoimmune disease, characterised by the interplay of vascular alterations, immune dysregulation, and fibrosis. The molecular changes and the clinical presentation of SSc are highly heterogeneous and vary considerably between individual patients. This heterogeneity has hampered efforts to reach a unified and pragmatic definition of disease modification in SSc. Using a consensus approach among SSc experts, the authors seek to identify current challenges in defining SSc disease modification. The definition of disease modification in SSc requires a nuanced approach that considers molecular, mechanistic, and clinical aspects. Disease-modifying treatments in SSc should target core pathways or cells rather than regulatory mechanisms. Disease-modifying treatments should show sustained effects on disease activity and prevent progression of damage across organs, manifestations, disease stages, and disease endotypes. The complex and variable nature of SSc needs to be reflected in preclinical drug development efforts and clinical trial designs to demonstrate disease-modifying effects of drug candidates for SSc. We herein provide a first framework for the definition of disease modification of vascular, inflammatory, and fibrotic domains in SSc. Advances in our understanding of the cellular and molecular mechanisms driving the progression of SSc will enable further refinement of the definition of disease modification and guide optimal preclinical modelling and innovative clinical trial design in future efforts.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Distler JHW, Assassi S, Gabrielli A, et al. Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design. Ann Rheum Dis. 2026. PMID: 42736088. doi:10.1016/j.ard.2026.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。